Cargando…
The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials
Background: Familial hypercholesterolemia (FH) lead to significant adverse effects in coronary arteries. Mipomersen is a second-generation antisense oligonucleotide that inhibits the synthesis of apolipoprotein B-100, an essential component of low density lipoprotein (LDL), and thus decreases the pr...
Autores principales: | Astaneh, Behrooz, Makhdami, Nima, Astaneh, Vala, Guyatt, Gordon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8304130/ https://www.ncbi.nlm.nih.gov/pubmed/34357325 http://dx.doi.org/10.3390/jcdd8070082 |
Ejemplares similares
-
Optimal management of familial hypercholesterolemia: treatment and management strategies
por: Nemati, Mohammad Hassan, et al.
Publicado: (2010) -
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
por: Bell, Damon A, et al.
Publicado: (2012) -
Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
por: Chambergo-Michilot, Diego, et al.
Publicado: (2022) -
Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2012) -
Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
por: McGowan, Mary P., et al.
Publicado: (2012)